Shares of Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) have earned an average rating of “Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.75.
Several research firms recently weighed in on ETTX. Zacks Investment Research raised Entasis Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research report on Thursday, April 4th. Wedbush reissued an “outperform” rating and set a $19.00 price objective on shares of Entasis Therapeutics in a research report on Tuesday, April 2nd.
A hedge fund recently bought a new stake in Entasis Therapeutics stock. Janney Montgomery Scott LLC purchased a new stake in Entasis Therapeutics Holdings Inc (NASDAQ:ETTX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 41,469 shares of the company’s stock, valued at approximately $169,000. Janney Montgomery Scott LLC owned approximately 0.32% of Entasis Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 65.02% of the company’s stock.
Entasis Therapeutics (NASDAQ:ETTX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.24). As a group, analysts predict that Entasis Therapeutics will post -3.95 EPS for the current fiscal year.
Entasis Therapeutics Company Profile
Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.
Featured Story: CD Ladder
Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.